You are here

  • Home
  • Archive
  • Volume 61, Issue 6
  • Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial
  1. Marie Joossens,
  2. Vicky De Preter,
  3. Vera Ballet,
  4. Kristin Verbeke,
  5. Paul Rutgeerts,
  6. Severine Vermeire
  1. Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospital Gasthuisberg, Catholic University Leuven (KUL), Leuven, Belgium
  1. Correspondence to Séverine Vermeire, Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium; severine.vermeire{at}uz.kuleuven.be

https://doi.org/10.1136/gutjnl-2011-300413

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    With great interest, we have read the manuscript by Benjamin et al1 on the effect of fructo-oligosaccharides in patients with active Crohn's disease (CD). We recently completed a single-centre randomised placebo-controlled trial with a similar study design. In our study, 67 patients with inactive and mild to moderately active CD were randomised to receive oligofructose-enriched inulin (OF-IN) or placebo 10 g twice daily for 4 weeks. Clinical disease activity was assessed …

    View Full Text

    Footnotes

    • Funding S Vermeire and V De Preter are postdoctoral fellows of the Fund for Scientific Research-Flanders, Belgium (F.W.O.-Vlaanderen). Sachets of oligofructose-enriched inulin and maltodextrin were provided by Beneo-Orafti, Belgium.

    • Competing interests None to declare.

    • Ethics approval The clinical trial was approved by the ethics committee of the Catholic University of Leuven (study number: ML4789).

    • Provenance and peer review Not commissioned; internally peer reviewed.